Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.

Corentin RichardJean-David FumetSandy ChevrierValentin DerangèreFanny LedysAurélie LagrangeLaure FavierBruno CoudertLaurent ArnouldCaroline TruntzerRomain BoidotFrançois Ghiringhelli

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Altogether, these data provide a validated biomarker that predicts the efficacy of nivolumab or pembrolizumab in patients with NSCLC. Our biomarker seems to be superior to PD-L1 labeling and TMB models.

Keyphrases

advanced non small cell lung cancer
copy number
small cell lung cancer
electronic health record
big data
gene expression
machine learning
brain metastases